Accountability and Transparency in Drug Approval

This chapter examines the FDA's past actions and accountability in drug approvals, particularly in the context of the opioid crisis and vaccine efficacy. It highlights the need for modern technology to improve safety, the importance of evidence-based medicine, and calls for greater transparency in health recommendations. Additionally, the chapter critiques the disparity in drug pricing in the U.S. compared to other countries and discusses the influence of pharmaceutical advertising on public perception and media coverage.